194 related articles for article (PubMed ID: 21575221)
21. Activated O2(•−) and H2O2 mediated cell survival in SU11274-treated non-small-cell lung cancer A549 cells via c-Met-PI3K-Akt and c-Met-Grb2/SOS-Ras-p38 pathways.
Liu Y; Shi QF; Ye YC; Tashiro S; Onodera S; Ikejima T
J Pharmacol Sci; 2012; 119(2):150-9. PubMed ID: 22673163
[TBL] [Abstract][Full Text] [Related]
22. c-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation.
Yu H; Li X; Sun S; Gao X; Zhou D
Biochem Biophys Res Commun; 2012 Oct; 427(3):659-65. PubMed ID: 23026049
[TBL] [Abstract][Full Text] [Related]
23. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
Moschetta M; Basile A; Ferrucci A; Frassanito MA; Rao L; Ria R; Solimando AG; Giuliani N; Boccarelli A; Fumarola F; Coluccia M; Rossini B; Ruggieri S; Nico B; Maiorano E; Ribatti D; Roccaro AM; Vacca A
Clin Cancer Res; 2013 Aug; 19(16):4371-82. PubMed ID: 23804425
[TBL] [Abstract][Full Text] [Related]
24. SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.
Saini M; Verma A; Mathew SJ
Cell Death Dis; 2018 Feb; 9(2):237. PubMed ID: 29445192
[TBL] [Abstract][Full Text] [Related]
25. Receptor tyrosine kinase MET as potential target of multi-kinase inhibitor and radiosensitizer sorafenib in HNSCC.
Beizaei K; Gleißner L; Hoffer K; Bußmann L; Vu AT; Steinmeister L; Laban S; Möckelmann N; Münscher A; Petersen C; Rothkamm K; Kriegs M
Head Neck; 2019 Jan; 41(1):208-215. PubMed ID: 30552828
[TBL] [Abstract][Full Text] [Related]
26. Activation of HGF/c-Met signaling by ultrafine carbon particles and its contribution to alveolar type II cell proliferation.
Chang CC; Chiu JJ; Chen SL; Huang HC; Chiu HF; Lin BH; Yang CY
Am J Physiol Lung Cell Mol Physiol; 2012 Apr; 302(8):L755-63. PubMed ID: 22245998
[TBL] [Abstract][Full Text] [Related]
27. Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells.
Liu Y; Yang Y; Ye YC; Shi QF; Chai K; Tashiro S; Onodera S; Ikejima T
J Pharmacol Sci; 2012; 118(4):423-32. PubMed ID: 22466960
[TBL] [Abstract][Full Text] [Related]
28. Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors.
Peron M; Lovisa F; Poli E; Basso G; Bonvini P
PLoS One; 2015; 10(7):e0132330. PubMed ID: 26147305
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation.
Kucerova L; Demkova L; Skolekova S; Bohovic R; Matuskova M
BMC Cancer; 2016 May; 16():308. PubMed ID: 27175734
[TBL] [Abstract][Full Text] [Related]
30. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
31. Syndecan-1 Shedding Inhibition to Protect Against Ischemic Acute Kidney Injury Through HGF Target Signaling Pathway.
Lu Z; Song N; Shen B; Xu X; Fang Y; Shi Y; Ning Y; Hu J; Dai Y; Ding X; Zou J; Teng J
Transplantation; 2018 Jul; 102(7):e331-e344. PubMed ID: 29557914
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of rhabdomyosarcoma cell and tumor growth by targeting specificity protein (Sp) transcription factors.
Chadalapaka G; Jutooru I; Sreevalsan S; Pathi S; Kim K; Chen C; Crose L; Linardic C; Safe S
Int J Cancer; 2013 Feb; 132(4):795-806. PubMed ID: 22815231
[TBL] [Abstract][Full Text] [Related]
33. (-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells.
Larsen CA; Dashwood RH
Arch Biochem Biophys; 2010 Sep; 501(1):52-7. PubMed ID: 20361925
[TBL] [Abstract][Full Text] [Related]
34. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.
Jagadeeswaran R; Ma PC; Seiwert TY; Jagadeeswaran S; Zumba O; Nallasura V; Ahmed S; Filiberti R; Paganuzzi M; Puntoni R; Kratzke RA; Gordon GJ; Sugarbaker DJ; Bueno R; Janamanchi V; Bindokas VP; Kindler HL; Salgia R
Cancer Res; 2006 Jan; 66(1):352-61. PubMed ID: 16397249
[TBL] [Abstract][Full Text] [Related]
35. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma.
Davis IJ; McFadden AW; Zhang Y; Coxon A; Burgess TL; Wagner AJ; Fisher DE
Cancer Res; 2010 Jan; 70(2):639-45. PubMed ID: 20068147
[TBL] [Abstract][Full Text] [Related]
36. Combined γ-tocotrienol and Met inhibitor treatment suppresses mammary cancer cell proliferation, epithelial-to-mesenchymal transition and migration.
Ayoub NM; Akl MR; Sylvester PW
Cell Prolif; 2013 Oct; 46(5):538-53. PubMed ID: 24033536
[TBL] [Abstract][Full Text] [Related]
37. Recruited T cells promote the bladder cancer metastasis via up-regulation of the estrogen receptor β/IL-1/c-MET signals.
Tao L; Qiu J; Slavin S; Ou Z; Liu Z; Ge J; Zuo L; Guancial EA; Messing EM; Chang C; Yeh S
Cancer Lett; 2018 Aug; 430():215-223. PubMed ID: 29684419
[TBL] [Abstract][Full Text] [Related]
38. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
Kanteti R; El-Hashani E; Dhanasingh I; Tretiakova M; Husain AN; Sharma S; Sharma J; Vokes EE; Salgia R
BMC Cancer; 2014 Mar; 14():185. PubMed ID: 24628993
[TBL] [Abstract][Full Text] [Related]
39. MET oncogene inhibition as a potential target of therapy for uveal melanomas.
Abdel-Rahman MH; Boru G; Massengill J; Salem MM; Davidorf FH
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3333-9. PubMed ID: 20164465
[TBL] [Abstract][Full Text] [Related]
40. Migration of oral squamous cell carcinoma cells are induced by HGF/c-Met signalling via lamellipodia and filopodia formation.
Yasui H; Ohnishi Y; Nakajima M; Nozaki M
Oncol Rep; 2017 Jun; 37(6):3674-3680. PubMed ID: 28440510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
